Table 1.
Clinical patient characteristics.
| Variable | Result |
|---|---|
| Characteristics of the study population | |
| Male gender | 5 (83.0%) |
| Age (years) | 57.0 (10.5) |
| APACHE II | 19.5 (6.1) |
| Body mass index | 29 (3) |
| Comorbidities | |
| History of smoking (n, %) | 2 (33.3%) |
| Arterial Hypertension (n, %) | 3 (50%) |
| Diabetes mellitus (n, %) | 2 (33.3%) |
| Chronic Obstructive Pulmonary Disease (n, %) | 0 (0%) |
| Malignant condition or immunosuppression (n, %) | 0 (0%) |
| Chronic kidney disease (n, %) | 0 (0%) |
| Liver disease (n, %) | 0 (0%) |
| Congestive heart disease (n, %) | 0 (0%) |
| Coronary heart disease (n, %) | 0 (0%) |
| Organ dysfunction and supportive treatment | |
| SOFA ICU admission | 5.2 (1.5) |
| PaO2/FIO2 ratio | 97.5 (14.6) |
| Prone position (n, %) | 6 (100%) |
| Sepsis (n, %) | 0 (0%) |
| Shock (n, %) | 1 (16.7%) |
| AKI (n, %) | 3 (50.0%) |
| CRRT (n, %) | 3 (50.0%) |
| Tocilizumab (n, %) | 4 (66.7%) |
| Corticoesteroids 2 mg/kg (n, %) | 1 (16,7%) |
| Anticoagulation (n, %) | 4 (66.7%) |
| VAP (n, %) | 2/6 (33.3%) |
| Hemoadsorption | |
| Duration hemoadsorption (h) | 16.0 (9.0) |
| N° sessions hemoadsorption | 1.2 (1.0) |
| Inflamatory parameters on admission | |
| DD (n.v. <0.5mcg/ml) | 559 (254–2643) |
| CRP (n.v. <0.5mg/dl) | 19.5 (13.4) |
| Ferritin (n.v. <336 mcg/L) | 967 (682–2116) |
| IL-6 (n.v. <4.3 pg/ml) | 1163 (52–2775) |
| Outcomes | |
| Days on mechanical ventilation | 15.2 (7.0) |
| ICU stay (days) | 17.2 (8.0) |
| ICU Mortality (n, %) | 2 (33.3%) |
| Inhospital Mortality (n, %) | 2 (33.3%) |
AKI, acute kidney injury; APACHE II, Acute Physiology and Chronic Health disease Classification System II; CRRT, continuous renal replacement therapy; CRP, C-reactive protein; DD, D-dimer; ICU, intensive care unit; SOFA, sequential organ failure assessment; VAP, ventilator-associated pneumonia.